U.S. markets closed
  • S&P 500

    3,933.92
    -7.34 (-0.19%)
     
  • Dow 30

    33,597.92
    +1.58 (+0.00%)
     
  • Nasdaq

    10,958.55
    -56.34 (-0.51%)
     
  • Russell 2000

    1,806.90
    -5.67 (-0.31%)
     
  • Crude Oil

    72.54
    +0.53 (+0.74%)
     
  • Gold

    1,797.70
    -0.30 (-0.02%)
     
  • Silver

    22.82
    -0.10 (-0.44%)
     
  • EUR/USD

    1.0510
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    3.4080
    -0.1050 (-2.99%)
     
  • GBP/USD

    1.2200
    -0.0005 (-0.04%)
     
  • USD/JPY

    136.5450
    +0.0210 (+0.02%)
     
  • BTC-USD

    16,872.86
    -230.60 (-1.35%)
     
  • CMC Crypto 200

    395.86
    -6.17 (-1.54%)
     
  • FTSE 100

    7,489.19
    -32.20 (-0.43%)
     
  • Nikkei 225

    27,468.35
    -218.05 (-0.79%)
     

What This News Means for Merck

What This News Means for Merck

In combination with Roche's (OTC: RHHBY) bevacizumab (Avastin), Merck's (NYSE: MRK) oncology medicine -- co-owned with AstraZeneca (NASDAQ: AZN) and known as Lynparza -- received the nod from China's National Medical Products Administration (NMPA) to treat patients with a form of advanced ovarian cancer. What led the NMPA to green-light the treatment combo?